In a concomitant setting SOT101 at 1 nM and the marketed therapeutic anti-CD38 antibody Daratumumab, the anti-CD20 antibody Obinutuzumab or the anti-EGFR antibody Cetuximab at 0.1, 1 and 10 nM were incubated with tumor cells for 20 h. Here, EGFR is linked to neoplasm.